10

loostyn oeesoe

a resolved stereoisomer thereof or mixture of one or more such stereoisomers, and pharmaceutically acceptable salts thereof, wherein

M is an immunophilin-binding group comprising a moiety of the formula II:

G is independently selected from the group consisting of:

Q comprises a moiety of formula, H, a naturally occurring macrocyclic FKBP ligand or derivative thereof, or is a synthetic FKBP ligand of formula III:

20 n = 1 or 2;

X = O, NH or CH<sub>2</sub>;

B1 and B2 are independently H or aliphatic, heteroaliphatic, aryl or heteroaryl;

Y = O, S, NH, -NH(C=O)-, -NH(C=O)-O-, -NH(SO<sub>2</sub>)-  $\alpha$ r NR<sup>3</sup>, or represents a covalent bond from R<sup>2</sup> to carbon 9;

R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> are the same or different and are independently aliphatic, 25 heteroaliphatic, aryl or heteroaryl; and,

L is a linker moiety covalently linking monomers M to Q or covalently linking  $M^{1}$  to M<sup>2</sup> through covalent bonds to either R<sup>1</sup> or R<sup>2</sup>, not necessarily the same in each of M<sup>1</sup> and  $M^2$ .

30